Niels Vandewalle

Niels Vandewalle is an active researcher at the Vrije Universiteit Brussel (VUB), affiliated with the Basic (bio-) Medical Sciences department within the Faculty of Medicine and Pharmacy. His work focuses on oncology, immunology, and hematological malignancies, particularly Acute Myeloid Leukemia (AML) and Multiple Myeloma. He leads projects on AXL targeting using single-domain antibodies and small molecule inhibitors, with applications in diagnosis and therapy. Vandewalle has supervised research by Kim De Veirman and collaborates extensively with teams in Belgium and internationally.

Research interests include tumor microenvironment dynamics, immune evasion mechanisms, and drug resistance in cancer. His recent studies explore adrenergic signaling's role in myeloma progression and the therapeutic potential of anti-CD40 agonists in activating dendritic cells. Vandewalle has received the Best Poster Presentation award (2024) and contributed to datasets published in high-impact repositories like Zenodo and NCBI GEO.

He actively participates in academic events, organizing charity quizzes and PhD symposiums. His projects (e.g., ANI400 and FWOSB110) emphasize translational research, aiming to bridge basic science and clinical applications in leukemia treatment.